{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:39:20Z","timestamp":1789774760731,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.biopha.2018.07.051","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:47:14Z","timestamp":1531842434000},"page":"1039-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Novel approaches in the treatment of diabetic cardiomyopathy"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0768-2772","authenticated-orcid":false,"given":"Durgalakshmi","family":"Sivasankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damal Kandadai","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.07.051_bib0005","series-title":"Global Report on Diabetes","year":"2016"},{"key":"10.1016\/j.biopha.2018.07.051_bib0010","series-title":"Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus (WHO\/NCD\/NCS\/99.2)","year":"1999"},{"key":"10.1016\/j.biopha.2018.07.051_bib0015","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic Glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.pharmtox.010909.105610","article-title":"Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy","volume":"50","author":"Bader","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0046-8177(84)80307-X","article-title":"Pathomorphologic aspects of muscular tissue in diabetes mellitus","volume":"15","author":"Fischer","year":"1984","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2337\/diacare.22.7.1186","article-title":"Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes","volume":"22","author":"Berg","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2018.07.051_bib0035","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1161\/01.RES.86.3.e50","article-title":"Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products","volume":"86","author":"Rojas","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2018.07.051_bib0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.abb.2003.09.005","article-title":"Activation of protein-bound copper ions during early glycation: a study on two proteins","volume":"420","author":"Argirova","year":"2003","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2018.07.051_bib0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2001.tb05634.x","article-title":"Protein glycation: the creation of catalytic sites for a free radical generation","volume":"928","author":"Yim","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2018.07.051_bib0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1050-1738(00)00077-3","article-title":"PPAR signaling in the control of cardiac energy metabolism","volume":"10","author":"Barger","year":"2000","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2018.07.051_bib0055","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.2337\/diabetes.51.4.1166","article-title":"Overexpression of the Sarcoplasmic Reticulum Ca2+-ATPase Improves Myocardial Contractility in Diabetic Cardiomyopathy","volume":"51","author":"Torst","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.07.051_bib0060","doi-asserted-by":"crossref","first-page":"H1529","DOI":"10.1152\/ajpheart.1996.270.5.H1529","article-title":"Altered Ca2+ handling in ventricular myocytes isolated from diabetic rats","volume":"270","author":"Lagadic-Gossmann","year":"1996","journal-title":"Am. J. Physiol.-Heart Circul. Physiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0065","doi-asserted-by":"crossref","first-page":"H2478","DOI":"10.1152\/ajpheart.00638.2005","article-title":"Depressed cardiac myofilament function in human diabetes mellitus","volume":"289","author":"Jweied","year":"2005","journal-title":"Am. J. Physiol.-Heart Circul. Physiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0075","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.yjmcc.2009.10.026","article-title":"ER stress in cardiovascular disease","volume":"48","author":"Minamino","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0080","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/db10-0351","article-title":"Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice","volume":"60","author":"Xie","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.07.051_bib0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/dc17-0755","article-title":"The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction","volume":"41","author":"Sandesara","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2018.07.051_bib0090","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12340","article-title":"Current perspectives in coronary microvascular dysfunction","volume":"24","author":"Shome","year":"2017","journal-title":"Microcirculation"},{"key":"10.1016\/j.biopha.2018.07.051_bib0095","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/CIRCULATIONAHA.110.938217","article-title":"Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition","volume":"121","author":"Widyantoro","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2018.07.051_bib0100","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2018.07.051_bib0105","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/dmrr.410","article-title":"Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or \u2013gamma agonists in a type 2 diabetic animal model","volume":"19","author":"Kim","year":"2003","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.biopha.2018.07.051_bib0110","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4065\/78.9.1088","article-title":"Thiazolidinedione-associated congestive heart failure, and pulmonary edema","volume":"78","author":"Kermani","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2018.07.051_bib0115","doi-asserted-by":"crossref","first-page":"C508","DOI":"10.1152\/ajpcell.00248.2012","article-title":"Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a","volume":"304","author":"Younce","year":"2013","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0120","series-title":"Diabetes in Control","article-title":"Battle of the GLP-1 agonists: liraglutide vs. exenatide","author":"Brooks","year":"2016"},{"key":"10.1016\/j.biopha.2018.07.051_bib0125","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.euje.2006.09.005","article-title":"Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: A comparativestudy","volume":"8","author":"Symeonides","year":"2007","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.biopha.2018.07.051_bib0130","article-title":"Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy","volume":"14","author":"Zhang","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2018.07.051_bib0135","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.07.051_bib0140","doi-asserted-by":"crossref","first-page":"H567","DOI":"10.1152\/ajpheart.00650.2012","article-title":"Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-\u03baB","volume":"304","author":"Wang","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0145","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing Pyruvate Dehydrogenase Flux as a Treatment for Diabetic Cardiomyopathy: A Combined 13C Hyperpolarized Magnetic Resonance and Echocardiography Study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.07.051_bib0150","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3109\/10715762.2010.499904","article-title":"The antioxidant edaravone attenuates ER-stress-mediated cardiac apoptosis and dysfunction in rats with autoimmune myocarditis","volume":"44","author":"Shimazaki","year":"2010","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.biopha.2018.07.051_bib0155","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/j.1582-4934.2012.01526.x","article-title":"Beneficial effects of edaravone, a novel antioxidant, in rats with dilated cardiomyopathy","volume":"16","author":"Arumugam","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.biopha.2018.07.051_bib0160","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00005344-200306000-00014","article-title":"Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus","volume":"4","author":"Hayashi","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0165","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1139\/cjpp-2015-0587","article-title":"The antioxidant edaravone prevents cardiac dysfunction by suppressing oxidative 2 stress in type 1 diabetic rats and in high glucose-induced injured H9c2 3 cardiomyoblasts","volume":"94","author":"Ji","year":"2016","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0170","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diabetes.50.6.1414","article-title":"IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-Mediated oxidative stress","volume":"50","author":"Kajstura","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2018.07.051_bib0175","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jacc.2006.07.022","article-title":"Attenuation by Metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy","volume":"48","author":"Cai","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0180","doi-asserted-by":"crossref","first-page":"H1876","DOI":"10.1152\/ajpheart.1997.272.4.H1876","article-title":"Modulation of SERCA2 expression by thyroid hormone and norepinephrine in cardiocytes: the role of contractility","volume":"272","author":"Muller","year":"1997","journal-title":"Am. J. Physiol.-Heart Circul. Physiol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0185","first-page":"A108","article-title":"Thioredoxin-interacting protein interacts with glucose transporters to regulate cardiac glucose metabolism","volume":"119","author":"Wang","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2018.07.051_bib0190","unstructured":"Shalev, Anath. Txnip: A Novel Approach to Prevent Diabetic Cardiomyopathy and Heart Failure. Research Portfolio Online Reporting Tools. 3R21HL089205-02S1."},{"key":"10.1016\/j.biopha.2018.07.051_bib0195","doi-asserted-by":"crossref","first-page":"E1133","DOI":"10.1152\/ajpendo.90944.2008","article-title":"Diabetes induces and calcium channel blockers prevent cardiac expression of the proapoptotic thioredoxin-interacting protein","volume":"296","author":"Chen","year":"2009","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2018.07.051_bib0200","first-page":"498","article-title":"Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure","author":"Nagaya","year":"2000","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2018.07.051_bib0205","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1253\/circj.CJ-08-0487","article-title":"Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure- a pilot study","volume":"73","author":"Nishikimi","year":"2009","journal-title":"Circ. J."},{"key":"10.1016\/j.biopha.2018.07.051_bib0210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.07.051_bib0215","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nm1582","article-title":"MicroRNA-133 controls cardiac hypertrophy","volume":"13","author":"Car\u00e8","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2018.07.051_bib0220","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ajpath.2011.04.034","article-title":"MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy","volume":"179","author":"Shen","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biopha.2018.07.051_bib0225","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s11596-013-1207-7","article-title":"MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes","volume":"33","author":"Zhao","year":"2013","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.biopha.2018.07.051_bib0230","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.febslet.2010.07.027","article-title":"miR-1\/miR-206 regulate Hsp60 expression contributing to glucose-mediated apoptosis in cardiomyocytes","volume":"584","author":"Shan","year":"2010","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2018.07.051_bib0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discovery"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217351430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217351430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T19:28:30Z","timestamp":1750879710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217351430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":47,"alternative-id":["S0753332217351430"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.051","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel approaches in the treatment of diabetic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.07.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}